Search

Your search keyword '"Pollak, Thomas"' showing total 517 results

Search Constraints

Start Over You searched for: Author "Pollak, Thomas" Remove constraint Author: "Pollak, Thomas" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
517 results on '"Pollak, Thomas"'

Search Results

1. Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study.

2. Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction

3. An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease

8. Utilising accessible and reproducible neurological assessments in clinical studies: Insights from use of the Neurological Impairment Scale in the multi-centre COVID-CNS study

11. Serum immune markers and transition to psychosis in individuals at clinical high risk

13. Neurological and psychiatric presentations associated with human monkeypox virus infection: A systematic review and meta-analysis

15. Central nervous system autoimmunity and infectious exposures in the early phases of psychosis

16. Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE study.

17. Immunological causes of obsessive-compulsive disorder: is it time for the concept of an “autoimmune OCD” subtype?

25. Dysregulated Lipid Metabolism Precedes Onset of Psychosis

27. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

29. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin

30. Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case–control comparison with patients testing negative

35. Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case–control comparison with patients testing negative

36. Post-COVID cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction: national prospective study

37. Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed methods study.

40. Damage markers in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease

41. Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE study

42. EXAMINING THE FEATURES OF NEUROLEPTIC MALIGNANT SYNDROME IN ANTI-NMDA RECEPTOR ENCEPHALITIS: A CASE-CONTROL STUDY

48. Prevalence of Neuroradiological Abnormalities in First-Episode Psychosis

49. Changes in immunoglobulin levels during clozapine treatment in schizophrenia

Catalog

Books, media, physical & digital resources